Clinical trials: Untreated
Classical Hodgkin Lymphoma, Lymphocyte-Depleted Classical Hodgkin Lymphoma
PET-Directed Therapy With Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Classical Hodgkin Lymphoma
The purpose of this research study is to evaluate a new drug pembrolizumab in combination with chemotherapy, for the treatment of newly diagnosed Hodgkin lymphoma.
- Conditions
- Classical Hodgkin Lymphoma, Lymphocyte-Depleted Classical Hodgkin Lymphoma, Lymphocyte-Rich Classical Hodgkin Lymphoma, Mixed Cellularity Classical Hodgkin Lymphoma
- Trial name
- NCT03226249
- Testing
- Computed Tomography, Dacarbazine, Doxorubicin Hydrochloride
- Where
- 4 sites in United States
- Volunteers
- 30 people
- Sponsor
- Northwestern University
Depression
Theta Burst Stimulation in Pharmacologically Untreated Patients as Sole Antidepressant Treatment
This is a randomized, controlled trial in which 72 patients with depressive disorder were treated in two study arms using the non-invasive brain stimulation method of intermittent thetaburst intermittent theta burst stimulation…
- Trial name
- TRUST (NCT05732298)
- Testing
- intermittend theta burst stimulation (iTBS)
- Where
- Germany
- Volunteers
- 72 people
- Sponsor
- University of Regensburg
Ann Arbor Stage II Mantle Cell Lymphoma, Ann Arbor Stage III Mantle Cell Lymphoma
Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma
This phase I trial tests the safety, side effects and best dose of glofitamab given with alternating cycles of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP)/ rituximab, dexamethasone, cytarabine…
- Conditions
- Ann Arbor Stage II Mantle Cell Lymphoma, Ann Arbor Stage III Mantle Cell Lymphoma, Ann Arbor Stage IV Mantle Cell Lymphoma
- Trial name
- NCT07444710
- Testing
- Biospecimen Collection, Cisplatin, Computed Tomography
- Volunteers
- 16 people
- Sponsor
- National Cancer Institute (NCI)
Peripheral T-cell Lymphoma
Study of Bortezomib Combined With ACVBP in Peripheral T-cell Lymphoma
The purpose of this study is to determine the efficacy and the safety profile and toxicity of a combination of Velcade™ (bortezomib) with a standard chemotherapy regimen (ACVBP [doxorubicin, cyclophosphamide, vindesine…
- Trial name
- NCT00136565
- Testing
- Velcade, Doxorubicin, Prednisone
- Where
- 5 sites in Belgium, France
- Volunteers
- 60 people
- Sponsor
- Lymphoma Study Association
Breast Cancer
Neoadjuvant Chemotherapy Including Sorafenib in Women With Previously Untreated Primary Breast Cancer
The purpose of this study is to determine the efficacy and safety of sorafenib in the neoadjuvant setting in patients with primary breast cancer
- Trial name
- SOFIA (NCT00548899)
- Testing
- Nexavar (Sorafenib)
- Where
- 9 sites in Germany
- Volunteers
- 36 people
- Sponsor
- GBG Forschungs GmbH
DLBCL - Diffuse Large B Cell Lymphoma
A Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patients With IPI 0-1
This is an open-label, multicentre, randomized phase II non-inferiority trial aiming to compare the efficacy and safety of 4 versus 6 cycles of CHP (administered at 21-day intervals), both in combination with 6 cycles of…
- Trial name
- NCT07034508
- Testing
- Polatuzumab Vedotin, Rituximab, Cyclophosphamide
- Where
- China
- Volunteers
- 134 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
ALK Gene Rearrangement Positive, Non-Squamous Non-Small Cell Neoplasm of Lung
Alectinib in Combination With Bevacizumab in ALK Positive NSCLC
This single-arm, open-label, phase II clinical study aims to evaluate the progression-Free Survival (PFS) of the combination of Alectinib plus Bevacizumab in untreated and first and second-line chemotherapy failed subjects with…
- Trial name
- NCT03779191
- Testing
- Alectinib, Bevacizumab
- Where
- Mexico
- Volunteers
- 41 people
- Sponsor
- Instituto Nacional de Cancerologia de Mexico
Lung Cancer
Combination Chemotherapy With or Without Filgrastim in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or…
- Trial name
- NCT00028925
- Testing
- filgrastim, carboplatin, topotecan hydrochloride
- Where
- 24 sites in United States, Canada
- Volunteers
- 27 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Ovarian Cancer, Fallopian Tube Cancer
A Study of the Efficacy and Safety of Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This multicenter, double-blind, 2-arm, randomized study will evaluate the efficacy and safety of bevacizumab plus paclitaxel and caboplatin compared with placebo plus paclitaxel and caboplatin in Chinese participants with newly…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT03635489
- Testing
- Paclitaxel, Bevacizumab, Carboplatin
- Where
- 16 sites in China
- Volunteers
- 100 people
- Sponsor
- Hoffmann-La Roche
Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma
Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas
The purpose of this study is to evaluate how safe and effective the combination of two different drugs (brentuximab vedotin and rituximab) is in patients with certain types of lymphoma.
- Conditions
- Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma
- Trial name
- NCT01805037
- Testing
- brentuximab vedotin, rituximab, laboratory biomarker analysis
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Northwestern University
Lymphoma
GM-CSF, Rituximab, and Combination Chemotherapy in Treating Patients With Previously Untreated Advanced Follicular Non-Hodgkin Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Trial name
- NCT00896519
- Testing
- rituximab, sargramostim, cyclophosphamide
- Volunteers
- 30 people
- Sponsor
- French Innovative Leukemia Organisation
Leukemia, Lymphoma
Pentostatin, Cyclophosphamide, and Rituximab With or Without Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
RATIONALE: Drugs used in chemotherapy, such as pentostatin and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00816595
- Testing
- bevacizumab, pegfilgrastim, rituximab
- Where
- 2 sites in United States
- Volunteers
- 68 people
- Sponsor
- Mayo Clinic
Primary Peritoneal Carcinoma, Tumor
Feasibility Study of Pazopanib in Combination With Chemotherapy in Gynaecological Tumors
This is an open-label, two-arm, multicenter feasibility study to evaluate the safety and tolerability of pazopanib in combination with carboplatin and paclitaxel in female subjects with newly diagnosed advanced gynaecological…
- Conditions
- Primary Peritoneal Carcinoma, Tumor, Epithelial Ovarian Cancer, Uterine Disease
- Trial name
- NCT00561795
- Testing
- pazopanib (GW786034), carboplatin, paclitaxel
- Where
- 5 sites in France, Germany
- Volunteers
- 12 people
- Sponsor
- GlaxoSmithKline
Lymphoma
Rituximab and Galiximab in Treating Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab and galiximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Trial name
- NCT00117975
- Testing
- galiximab, rituximab
- Where
- 68 sites in United States
- Volunteers
- 62 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Thymic Carcinoma, Thymoma
Ramucirumab and Carbo-Paclitaxel for Untreated Thymic Carcinoma / B3 Thymoma With Carcinoma (RELEVENT)
This is a multicentric study. All patients with TET (thymic epithelial tumors) of any histological type will participate in the study.
- Trial name
- RELEVENT (NCT03921671)
- Testing
- Ramucirumab
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- Claudia Proto
Waldenstrom's Macroglobulinemia
Study of Ibrutinib in Patients With Symptomatic, Previously Untreated Waldenstrom's Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome Sequencing
This research study is studying a drug called ibrutinib as a possible treatment for untreated Waldenstrom's Macroglobulinemia (WM).
- Trial name
- NCT02604511
- Testing
- Ibrutinib
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- Dana-Farber Cancer Institute
Leukemia
Combination Chemotherapy and Tipifarnib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
RATIONALE: Drugs used in chemotherapy, such as cytarabine, daunorubicin, and etoposide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00124644
- Testing
- cytarabine, daunorubicin hydrochloride, etoposide
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Carcinoma, Small Cell
Trial of Belotecan/Cisplatin in Chemotherapy Naive Small Cell Lung Cancer Patient
Belotecan (Camtobell, CKD-602, Chong Kun Dang Pharm., Korea) is a new camptothecin derivative, that exhibits anticancer effects by inhibiting topoisomerase I.
- Trial name
- COMBAT (NCT00826644)
- Testing
- Belotecan, Etoposide, Cisplatin
- Where
- South Korea
- Volunteers
- 147 people
- Sponsor
- Chonnam National University Hospital
Sarcoma
Combination Chemotherapy in Treating Patients Undergoing Surgery for Newly Diagnosed High-Grade Osteosarcoma
RATIONALE: Drugs used in chemotherapy, such as ifosfamide, methotrexate, cisplatin, and doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00645632
- Testing
- cisplatin, doxorubicin hydrochloride, ifosfamide
- Volunteers
- 60 people
- Sponsor
- Mayo Clinic
Multiple Myeloma
First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment With Velcade
The purpose of this study is to study the MRD status after VELCADE based induction therapy (VELCADE, lenalidomide, dexamethasone or VELCADE, liposomal doxorubicin, dexamethasone) in patients with previously untreated multiple…
- Trial name
- NCT01215344
- Testing
- VELCADE, Lenalidomide, Dexamethasone
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.